PeptideLabs Logo
PeptideLabs
All profiles

GHRP-2

Peptide · Endocrine signals

Stimulates growth-hormone release in research models and may affect other endocrine signals.

Not FDA/EMA approvedWADA
LibraryNo account · this device only

Also known as: Pralmorelin · Growth hormone-releasing peptide 2

Use at a glance

GHRP-2

Stimulates growth-hormone release in research models and may affect other endocrine signals.

No reliable information available

No sufficiently clear source for amounts, intervals and cycles can be assigned to this profile. Concrete stages are therefore intentionally omitted; an invented number would be more dangerous than a visible data gap.

How is it used?
Studies or online reports describe particular uses. They do not establish a general instruction for vendor products.
Does it need mixing?
No validated recipe is established for arbitrary research vials. The calculator shows concentration, not suitability or shelf life.
View preparationCheck sources
More factsPeptide · Endocrine signals
Classification
Peptide · Endocrine signals
Research focus
Stimulates growth-hormone release in research models and may affect other endocrine signals.
Evidence
Early human data
Status
Not FDA/EMA approved

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Schedule explained in detailCommunity/research information only

Amount status

No published detail page in the reference source, and no validated subcutaneous or nasal human protocol. Old intravenous challenge studies are not a community dose.

Profile evidence level: early_human.

Timing

No clinically confirmed timing; GH, ACTH, cortisol and prolactin effects may overlap.

No individual recommendation.

Cycle/duration

No seriously standardised cycle or long-term safety framework.

No individual recommendation.

Mixing & calculations

No validated recipe is established for arbitrary research vials. The calculator shows concentration, not suitability or shelf life.

All preparation informationProduct details and calculation examples from the available sources.

No dependable vial/BAC-water table. Study formulations and unregulated research material are not interchangeable.

Reconstitution & quantitiesOpen basics, units and sources
Explained in very simple termsBefore reading any number: this page reports what a product label, study or online community states. It does not say what any person should use.

Amount

mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.

Interval

The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.

Cycle

A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.

Reconstitution

Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.

Not a guide to misuse

All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.

Research, risks & more detailsMechanism, adverse effects, storage, comparisons and common questions.

Mechanism: what is supported and what does not follow

Ghrelin receptor agonist and GH secretagogue

GHRP-2 is classified as “Ghrelin receptor agonist and GH secretagogue”. Stimulates growth-hormone release in research models and may affect other endocrine signals. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Ghrelin secretagogue

This checks how a substance stimulates growth hormone release through the ghrelin receptor, similar to how the body's own hunger hormone does. Measures include growth hormone peaks in blood and appetite changes.

02

Growth hormone release

This studies how much growth hormone the pituitary gland releases into the blood after a stimulus, similar to measuring how much water flows out when a tap is briefly opened. Researchers typically draw blood samples at several time points to capture the size and timing of the release.

03

Growth-axis amplification

Researchers study how a substance amplifies the natural hormone chain from brain to pituitary to growth hormone, rather than supplying growth hormone directly. Hormone levels over time and muscle or fat mass are measured.

What communities discuss

These themes describe discussions and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Bodybuilding forums

Here, muscle growth, strength gains, and recovery times are compared between different growth and repair peptides, often based on personal training logs. Vendor and user claims about muscle gains are anecdotal experience, not controlled study results.

Doping and sports forums

The use of performance-enhancing peptides in sport is discussed, including experiences with competition testing and regulatory ban lists. Personal experience does not establish efficacy or safety and does not replace official rule checks.

Source and purity discussion

Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.

Adverse effects and safety risks

  • Interference with GH, IGF-1 or other hormone axes may cause oedema, joint or nerve symptoms, glucose intolerance, blood-pressure and hormonal changes; dependable human data are absent for many research substances.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Do not self-use / obtain clinical review

  • Active or previous malignancy, uncontrolled diabetes, intracranial disease, pregnancy/breastfeeding and hormone-sensitive disease require specialist assessment; approved products have specific contraindications.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • In medically justified use, IGF-1, fasting glucose/HbA1c, blood pressure, weight/oedema, thyroid and indication-specific hormones may be relevant; this is not a self-testing schedule.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Early human data

Limited human data exist; the FDA lists serious events while noting that causality has not been established.

Clinical evidence

Some early, usually small human studies or observations exist, but they do not yet count as robust proof of efficacy.

GHRP-2 may influence other endocrine signals beyond growth hormone, unlike more selectively discussed secretagogues.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and common errors

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Not FDA/EMA approved

No FDA- or EMA-approved medicinal product; efficacy and safety are not established.

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile